Lyophilized drugs, also known as freeze-dried drugs, are water-soluble drugs that are freeze-dried for longer shelf life and stability. This drying technique removes water from the pharmaceutical product after it is frozen so that the product can be stored for an extended period without refrigeration. Lyophilized drugs have applications in parenteral drugs, biologics, and antibiotics where longer shelf life without refrigeration is required.
The global lyophilized drugs market is estimated to be valued at US$ 366.11 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Growing demand for long shelf-life drugs: The growing demand for long shelf-life drugs that do not require refrigeration during transportation or storage is expected to drive the growth of the lyophilized drugs market during the forecast period. Lyophilization helps extend the shelf life of drugs from months to years at room temperature without refrigeration, thus offering stability and longer expiry periods. This technique allows drugs to stay protected and responsive even without temperature-controlled supply chains.
This increased demand can be attributed to two key drivers referenced in the heading – longer shelf life afforded by lyophilization. Lyophilization removes water from drugs through sublimation under vacuum pressure which prevents chemical decomposition of drugs. The lack of water and low temperature storage conditions prevent microbial growth, allowing drugs to retain potency for extended periods. This makes lyophilization increasingly useful for biologics and antibiotics supplied to remote locations without consistent access to cold chain infrastructure.
The global lyophilized drugs market is segmented into application and product type. The application segment is further divided into pharmaceutical, biotechnology and food industry. Among these, the pharmaceutical segment holds the largest market share of over 60% as of 2024. This segment is dominating due to increase in demand for freeze-dried drugs in hospitals and clinics as these drugs can be stored without refrigeration for longer periods.
Political: Governments across countries are investing significantly in the healthcare sector which is encouraging new players to enter the lyophilized drugs market and boosting investments in R&D.
Economic: Rising disposable income is increasing healthcare expenditure. Growing aging population requiring more medical treatment is fueling market growth.
Social: Increasing awareness about benefits of lyophilized drugs such as longer shelf life without refrigeration is driving preference for these drugs.
Technological: Advancements in freeze-drying equipment and technologies are helping lower manufacturing costs and improve drug efficacy. Continuous technological upgrades are expanding applications of lyophilized drugs.
The Global Lyophilized Drugs Market Size estimated to be valued at US$ 366.11 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031.
Regional analysis: North America region dominates the global market and is estimated to account for around 35% share in 2024 owing to presence of major players and high healthcare spending in the US and Canada.
Key players related content: Key players operating in the lyophilized drugs market are BASF SE, Evonik Industries AG, Clariant AG, DuPont de Nemours, Inc., Albemarle Corporation, Arkema SA, Johnson Matthey PLC, Mitsubishi Chemical Corporation, Honeywell International Inc., Shell Catalysts & Technologies, W. R. Grace & Co., Haldor Topsoe A/S, and Dow Chemical Company. These players are focusing on launching new products and expanding regional footprint to strengthen their market position.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it